Deciphera Pharmaceuticals, Inc. Aktie News

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Deciphera Pharmaceuticals, Inc. (NasdaqGS: DCPH) to ONO Pharmaceutical Co., Ltd. Under the terms of the proposed transaction, shareholders of Deciphera will receive $25.60 in cash for each share of Deciphera that ...

Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets.

NEW YORK , April 29, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) , relating to its proposed m...

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical (TYO: 4528) announced plans of buying it for $2.4 billion.  Deciphera Pharmaceuticals stock valued at $25.60 The cash offer values each share of Deciphera Pharmaceuticals at $25.60.

Deciphera Pharmaceuticals (NASDAQ: DCPH ) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical. This deal has ONO Pharmaceutical acquiring Deciphera Pharmaceuticals for $25.60 per share in cash.

MILWAUKEE , April 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Deciphera (NASDAQ: DCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with ONO. Click here to learn how to join the https://www.ademilaw.com/case/deciphera-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Deciphera stock rocketed to a three-year high Monday after Ono Pharmaceutical agreed to buy it for $2.4 billion.

Deciphera Pharmaceuticals is being bought by Japan's ONO Pharmaceutical in a deal valued at $2.4 billion.